New York State Common Retirement Fund Purchases 823,456 Shares of Grifols, S.A. (NASDAQ:GRFS)

New York State Common Retirement Fund boosted its position in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 50.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,452,728 shares of the biotechnology company's stock after acquiring an additional 823,456 shares during the period. New York State Common Retirement Fund owned approximately 0.36% of Grifols worth $17,439,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Ballentine Partners LLC acquired a new stake in Grifols during the first quarter valued at approximately $77,000. Cerity Partners LLC boosted its holdings in Grifols by 22.8% during the first quarter. Cerity Partners LLC now owns 22,254 shares of the biotechnology company's stock valued at $158,000 after purchasing an additional 4,129 shares in the last quarter. Envestnet Asset Management Inc. boosted its holdings in Grifols by 7.6% during the first quarter. Envestnet Asset Management Inc. now owns 274,693 shares of the biotechnology company's stock valued at $1,953,000 after purchasing an additional 19,447 shares in the last quarter. Compass Wealth Management LLC acquired a new position in shares of Grifols in the 1st quarter worth approximately $541,000. Finally, Sequoia Financial Advisors LLC boosted its holdings in shares of Grifols by 14.9% in the 1st quarter. Sequoia Financial Advisors LLC now owns 26,230 shares of the biotechnology company's stock worth $186,000 after acquiring an additional 3,399 shares in the last quarter.

Analyst Ratings Changes

Several research analysts have recently commented on the company. JPMorgan Chase & Co. boosted their target price on Grifols from $7.60 to $10.30 and gave the stock a "neutral" rating in a report on Tuesday, June 17th. Wall Street Zen raised Grifols from a "buy" rating to a "strong-buy" rating in a report on Monday, July 7th.

Grifols Stock Down 1.1%

Shares of Grifols stock traded down $0.11 during trading hours on Friday, reaching $9.94. 796,127 shares of the company's stock were exchanged, compared to its average volume of 1,046,901. The company has a 50 day moving average of $8.73 and a two-hundred day moving average of $7.84. Grifols, S.A. has a fifty-two week low of $6.19 and a fifty-two week high of $10.30. The company has a current ratio of 2.60, a quick ratio of 0.97 and a debt-to-equity ratio of 1.13. The stock has a market cap of $6.83 billion, a P/E ratio of 8.50, a P/E/G ratio of 0.36 and a beta of 0.55.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.